<DOC>
	<DOC>NCT01246453</DOC>
	<brief_summary>1. Objectives: - Main objective: To evaluate the efficacy and safety of intrapleural alteplase vs urokinase in patients with complex complicated parapneumonic pleural effusion and empyema. - To evaluate the pleural and plasmatic levels of the fibrinolytic system markers after the treatment with alteplase vs urokinase - To evaluate the safety of alteplase in the treatment of complex complicated parapneumonic pleural effusion and empyema 2. Design: Multicentric, randomized, parallel, controlled and double blind 3. Main variable: Percentage of curation 4. Study population and number of patients: 204 patients with complex complicated parapneumonic pleural effusions and empyema 5. Duration of the treatment: Three days (main variable), and optional three days (secondary variable)</brief_summary>
	<brief_title>Efficacy and Security of Intrapleurally Alteplase vs Urokinase for the Treatment of Complicated Parapneumonic Effusion and Empyema</brief_title>
	<detailed_description />
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Empyema</mesh_term>
	<mesh_term>Pleural Diseases</mesh_term>
	<mesh_term>Empyema, Pleural</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Empyema and Complex Complicated Parapneumonic Pleural Effusion Pregnancy or breastfeeding Critically illness Systemic anticoagulant treatment Coagulation Disorder Bronchopleural fistula Active bleeding Recent punction of noncompressive artery Stroke in the last 6 months Major intervention o major traumatism in the last 6 weeks Hypersensibility to urokinase or alteplase Severe Liver or kidney failure Inclusion in another interventional study in the last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>